Director General’s Message

As IVI’s third Director General, I am honored to lead a team of more than 300 professionals representing over 35 nationalities, alongside 44 countries and the World Health Organization as members of IVI, all working together toward a common goal of advancing science for impact and improving the health of people around the world.
IVI is a unique organization with a singular mission: to discover, develop, and deliver safe, effective, and affordable vaccines—empowering vaccine equity, impact, and sustainability globally.
We are an independent international organization originally established at the initiative of the United Nations Development Programme in 1997. We are accountable to a Board of Trustees and our members. We are also a research institute and product development partnership in practice, specializing in all aspects of the vaccine value chain, from laboratory research to vaccine development, epidemiology and surveillance, and vaccine effectiveness.
Our headquarters is in Seoul, Republic of Korea, and we have a Europe Regional Office in Stockholm, Sweden; an Africa Regional Office in Kigali, Rwanda; an Austria Country Office in Vienna; and the Kenya Country and AVEC Africa Project Office in Nairobi. IVI also co-founded the Hong Kong Jockey Club Global Health Institute in Hong Kong SAR, China, and has Collaborating Centers in Bhutan, Burkina Faso, Ethiopia, Ghana, Madagascar, and Nepal. Our field programs span six continents and promote collaborative, sustainable partnerships with governments, academic institutions, industry, philanthropy, and other global health agencies.
Through public-private partnerships, IVI has developed two vaccines for global health: the world’s first low-cost oral cholera vaccine and the Vi-DT typhoid conjugate vaccine. IVI has also led clinical development for five WHO-prequalified vaccine products. These achievements demonstrate how vaccine science, technology transfer, clinical development, and partnerships can expand access to vaccines that address urgent global health needs.
As of 2025, IVI had completed 14 vaccine technology transfer projects involving six vaccines and had trained more than 9,290 professionals in person and online.
Our full vaccine research and development portfolio includes vaccines at all stages of preclinical and clinical development, prioritizing infectious diseases that disproportionately affect populations in low- and middle-income countries. IVI was founded to prevent and eliminate infectious diseases associated with poverty, and since our founding in 1997, we have remained steadfast in that mandate while expanding our work in pandemic preparedness and health security.
The work toward a healthier world made possible by vaccination, available to everyone, everywhere, continues—and we are grateful to do it with you.
Sincerely,

Jerome H. Kim, M.D.
Director General

